title: Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response.
abstract: Unlike the pp65 protein of human cytomegalovirus (CMV), which has an immunodominant peptide, pp65(495-503), recognized by human CD8(+) cells in the context of HLA A*0201, the fine peptide specificity for CMV IE1 has shown no such immunodominance. With the use of transgenic HLA A*0201/Kb and HHD II mice, a selected pool of IE1 peptides, including IE1(p256-264), IE1(p297-304), and IE1(p316-324), were shown to stimulate cytolytic T-lymphocyte lysis in the context of HLA A*0201. Based on an intracellular gamma interferon response, IE1(p297-304), a previously unrecognized CD8 epitope, triggered a prominent response to CMV IE1 in HLA A*0201 subjects.
authors.affiliation: Department of Virology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.
authors.forename: Ghislaine
authors.initials: G
authors.lastname: Gallez-Hawkins
authors.forename: Maria C
authors.initials: MC
authors.lastname: Villacres
authors.forename: Xiuli
authors.initials: X
authors.lastname: Li
authors.forename: Margaret C
authors.initials: MC
authors.lastname: Sanborn
authors.forename: Norma A
authors.initials: NA
authors.lastname: Lomeli
authors.forename: John A
authors.initials: JA
authors.lastname: Zaia
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D003587:Cytomegalovirus / Q000235:genetics / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000276:immunology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000235:genetics; D015234:HLA-A Antigens / Q000235:genetics*; D015789:HLA-A2 Antigen; D006801:Humans; D017874:Immediate-Early Proteins / Q000235:genetics / Q000276:immunology*; D016056:Immunodominant Epitopes / Q000235:genetics; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000096:biosynthesis; D051379:Mice; D008822:Mice, Transgenic; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology; D010750:Phosphoproteins / Q000008:administration & dosage / Q000235:genetics; D011994:Recombinant Proteins; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics; D014763:Viral Matrix Proteins / Q000008:administration & dosage / Q000235:genetics; D014764:Viral Proteins; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics
chemical_list: D015234:HLA-A Antigens; C435939:HLA-A*02:01 antigen; D015789:HLA-A2 Antigen; C088645:IE1 protein, cytomegalovirus; D017874:Immediate-Early Proteins; D016056:Immunodominant Epitopes; D010446:Peptide Fragments; D010750:Phosphoproteins; D011994:Recombinant Proteins; D019444:Vaccines, DNA; D014763:Viral Matrix Proteins; D014764:Viral Proteins; D014765:Viral Vaccines; C065418:cytomegalovirus matrix protein 65kDa; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor